TransPharma Medical Ltd. announced the completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II. 

The Phase 1b study was a single-dose, four-way cross over study designed to evaluate the pharmacokinetic (PK) profile, safety and tolerability of ViaDor-GLP1 agonist in diabetic patients using TransPharma's extended release state-of-the-art film patch of GLP1 agonist. The study was performed on 14 type II diabetic patients, and evaluated a once daily application of three patch formulations, as Exenatide.

The results of the study demonstrate ViaDor-GLP1 agonist to be safe and well-tolerated with a preferable extended PK profile compared to exenatide. Transdermal applications of ViaDor-GLP1 agonist resulted in therapeutic blood levels for approximately 20 hours compared to 6 hours post injection of exenatide. Concurrently, post postprandial glucose levels were consistent with ViaDor-GLP1 extended PK profiles. 

Source:

TransPharma Medical Ltd.